Please ensure Javascript is enabled for purposes of website accessibility

Elan Rejects Royalty Pharma's Acquisition Offer

By Tim Brugger - Apr 22, 2013 at 10:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Irish biotechnology firm says the unsolicited offer "undervalues the company."

After confirming an unsolicited takeover bid from privately held investment firm Royalty Pharma in late February, Ireland-based Elan (ELN) announced today that its board has unanimously rejected the offer.

According to Elan, Royalty Pharma's offer, via its subsidiary Echo Pharma Acquisitions, was for "$11.25 or less" for each outstanding share of Elan stock. The deal valued Elan at approximately $6.7 billion.

Elan is advising its shareholders to "take no action in relation to the Echo Pharma Acquisition Limited [Royalty Pharma] offer" until Elan communicates with shareholders after the publication of Royalty Pharma's formal "offer document."

"The offer from Royalty Pharma grossly undervalues Elan's current business platform and our future prospects. As a result the Board unanimously and without reservation rejected the offer," Elan Chairman Robert Ingram was quoted as saying.

Last week, Elan concluded a Dutch auction to buy back some of its own shares, ending up accepting for repurchase 88.9 million shares, representing 14.8% of its existing issued shares, at a price of $11.25 per share, for an aggregate purchase price of $1 billion.

Royalty Pharma had originally offered $11 per share and said it might increase that after the Dutch auction. It confirmed Thursday that its offer price was $11.25 per share.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Elan Corporation Limited Stock Quote
Elan Corporation Limited

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.